View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 28, 2021updated 06 Oct 2021 5:47am

US FDA grants EUA for ANP Technologies’ Covid-19 rapid test kit

The NIDS Covid-19 test kit detects the SARS-CoV-2 nucleocapsid protein in nasal swab specimens using highly sensitive antibodies.

The US F ood and Drug Administration (F DA) has granted emergency use authorization (EUA) for ANP Technologies’ NIDS COVID-19 Antigen Rapid Test Kit.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The test is a lateral flow immunoassay (LF A) that is developed using ANP ’s Nano-Intelligent Detection System (NIDS) platform technology for the detection of SARS-CoV-2 from direct nasal swabs using NIDS Swab Buffer.

It uses highly sensitive antibodies for the detection of the SARS-CoV-2 nucleocapsid protein in nasal swab specimens.

ANP chief technology officer and president Ray Yin said: “The NIDS COVID-19 Antigen Rapid Test was developed using our NIDS technology platform that was initially developed for the rapid detection of various biological warfare agents for the US military more than a decade ago.

“With the Covid-19 pandemic, ANP quickly configured its NIDS platform for the detection of SARS-CoV-2 antigen and achieved outstanding performance under the funding from the Department of Defense and the RADx initiative.”

The NIDS COVID-19 Antigen Rapid Test Kit provides a visual result in 15 minutes based on the presence or absence of pink/purple-coloured lines.

The company stated that the test is also effective in the detection of many other Covid-19 variants, including Delta.

ANP business development and contracts senior director Greg Whitham said: “With this pivotal F DA authorisation, ANP is now focusing on the large-scale production of the test kits and welcomes all partnerships and collaborations to improve testing production capacity and speed to market, which is paramount to get folks back to work/school and reopen the economy.”

The NIDS test is authorised for use at the point of care and does not differentiate between SARS-CoV and SARS-CoV-2.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network